

References

I-37

1. Reich K, Papp K, Griffiths C, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis. *Brit J Derm*. 2013;168(4):844-854.
2. Ustekinumab (Stelara®) also indicated for active psoriatic arthritis (PsA). Janssen Biotech, Inc. clinical trial summary - PSUMMIT I. 2013.
3. Stelara [Product Information], Horsham, PA. Janssen Biotech, Inc.; September 2013.
4. McInnes I, Kavanaugh A, Gottlieb A, et al.; PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet*. 2013;382(9894):780-789.
5. Kimball A, Papp K, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. *Eur Acad Derm Venereol*. 2013;27(12):1535-1545.
6. Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease-The McGill experience. *J Crohns Colitis*. 2014;1-7.
7. Poddubnyy D, Hermann K, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). *Ann Rheum Dis*. 2014;73(5):817-823.
8. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. *Ann Rheum Dis*. 2014;73(6):990-999.
9. Micromedex® Healthcare Series. DrugDex Compendium®.
10. Simon E, Ghosh S, Lacucci M, et al. Ustekinumab for the treatment of Crohn's disease: can it find its niche? *Therap Adv Gastroenterol*. 2016;9(1):26-36.
11. Chiu H, Chu T, Cheng Y, et al. The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab. *PLoS ONE*. 2015; 10(11): e0142930.
12. Richter L, Vujic I, Sesti A, et al. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. *JDDG*. 2016;309-317.
13. Deepak P, Loftus EV. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy. *Drug Des Devel Ther*. 2016;3685-3698.
14. MICROMEDEX®SOLUTIONS Compendia. 2017. Ustekinumab.
15. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Ustekinumab.
16. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. Healthcare. 2016.

17. Torres T, Faria R. Ustekinumab: The “new kid on the block” in the treatment of psoriatic arthritis. *Drug Development Research*. 2015;428–431.